Bi-lateral local renal delivery for treating congestive heart failure and for BNP therapy
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61M-025/00
출원번호
UP-0129101
(2005-05-13)
등록번호
US-7585836
(2009-09-22)
발명자
/ 주소
Goodson, IV, Harry Burt
Patel, Samir R.
Ball, Craig A.
Elkins, Jeffrey M.
인용정보
피인용 횟수 :
5인용 특허 :
178
초록
The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and methods of use.
대표청구항▼
What is claimed is: 1. A method comprising: placing a bifurcated renal infusion catheter within a patient, such that a first distal infusion branch of the catheter is disposed within a first renal artery and a second distal infusion branch of the catheter is disposed within a second renal artery; a
What is claimed is: 1. A method comprising: placing a bifurcated renal infusion catheter within a patient, such that a first distal infusion branch of the catheter is disposed within a first renal artery and a second distal infusion branch of the catheter is disposed within a second renal artery; and locally administering a natriuretic peptide into both renal arteries of the patient via the bifurcated renal infusion catheter, wherein the patient is at risk of developing or is suffering from at least one condition selected from the group consisting of congestive heart failure, dyspnea, elevated pulmonary capillary wedge pressure, chronic renal insufficiency, acute renal failure, cardiorenal syndrome, and diabetes mellitus. 2. The method as in claim 1, wherein the local delivery into both renal arteries occurs simultaneously. 3. The method as in claim 1, wherein the peptide is administered under conditions selected to reduce the risk of systemic side effects including hypotension. 4. The method as in claim 1, wherein the peptide is delivered in form of a drug or pharmaceutical composition. 5. The method as in claim 4, wherein the drug is delivered in bolus form at a dosage of about 1 to 5 mcg/kg. 6. The method as in claim 4, wherein the drug is delivered via continuous administration at a dosage of about 0.005 to 0.05 mcg/kg/min. 7. The method as in claim 4, wherein the drug is delivered through a bolus form at a dosage of about 1 to 5 mcg/kg in combination with continuous administration at a dosage of about 0.005 to 0.05 mcg/kg/min. 8. The method as in claim 1, wherein the natriuretic peptide is selected from the group consisting of BNP, ANP, and CNP. 9. The method of treating a patient comprising: bilaterally cannulating both renal arteries of a patient with a bifurcated renal infusion catheter, such that a first distal infusion branch of the infusion catheter is disposed within a first renal artery of the patient and a second distal infusion branch of the infusion catheter is disposed within a second renal artery of the patient; and locally administering a natriuretic peptide into both renal arteries of the patient via a bifurcated renal infusion catheter, wherein the patient is at risk of developing or is suffering from at least one condition selected from the group consisting of congestive heart failure, dyspnea, elevated pulmonary capillary wedge pressure, chronic renal insufficiency, acute renal failure, cardiorenal syndrome, and diabetes mellitus. 10. The method as in claim 9, wherein the patient is at risk of developing at least one condition selected from the group consisting of congestive heart failure, dyspnea, elevated pulmonary capillary wedge pressure, chronic renal insufficiency, acute renal failure, cardiorenal syndrome, and diabetes mellitus. 11. The method as in claim 9, wherein the patient is suffering from least one condition selected from the group consisting of congestive heart failure, dyspnea, elevated pulmonary capillary wedge pressure, chronic renal insufficiency, acute renal failure, cardiorenal syndrome, and diabetes mellitus. 12. The method as in claim 9, wherein the peptide is administered under conditions selected to reduce the risk of systemic side effects including hypotension. 13. The method as in claim 9, wherein the peptide is delivered in form of a drug or pharmaceutical composition. 14. The method as in claim 13, wherein the drug is delivered in bolus form at a dosage of about 1 to 5 mcg/kg. 15. The method as in claim 13, wherein the drug is delivered via continuous administration at a dosage of about 0.005 to 0.05 mcg/kg/min. 16. The method as in claim 13, wherein the drug is delivered through a bolus form at a dosage of about 1 to 5 mcg/kg in combination with continuous administration at a dosage of about 0.005 to 0.05 mcg/kg/min. 17. The method as in claim 9, wherein the natriuretic peptide is selected from the group consisting of BNP, ANP, and CNP. 18. The method of treating a patient comprising: locally administering a natriuretic peptide into both renal arteries of the patient via a bifurcated renal infusion catheter, wherein the patient is at risk of developing or is suffering from at least one condition selected from the group consisting of congestive heart failure, dyspnea, elevated pulmonary capillary wedge pressure, chronic renal insufficiency, acute renal failure, cardiorenal syndrome, and diabetes mellitus. 19. The method as in claim 1, wherein the patient is suffering from acute renal failure. 20. The method as in claim 1, wherein the patient is at risk of developing acute renal failure. 21. The method as in claim 1, wherein the patient has a serum creatinine level above baseline. 22. The method as in claim 9, wherein the patient is suffering from acute renal failure. 23. The method as in claim 9, wherein the patient is at risk of developing acute renal failure. 24. The method as in claim 9, wherein the patient presents a percentage rise in serum creatinine of at least 25% or an absolute rise in serum creatinine of at least 0.5 mg/dl, or both, within 72 hours. 25. The method as in claim 18, wherein the patient is suffering from acute renal failure. 26. The method as in claim 18, wherein the patient is at risk of developing acute renal failure. 27. The method as in claim 18, wherein the patient presents a percentage rise in serum creatinine of at least 25% or an absolute rise in serum creatinine of at least 0.5 mg/dl, or both, within 72 hours.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (178)
Bandurco Victor T. (Bridgewater NJ) Levine Seymour D. (North Brunswick NJ) Mulvey Dennis M. (New Hope PA) Tobia Alfonso J. (Doylestown PA), 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use.
Elkins,Jeffrey M.; Goodson,Harry B.; Maguire,Mark A.; Valencia,Aurelio; Patel,Samir R., Apparatus and method for inserting an intra-aorta catheter through a delivery sheath.
Elkins,Jeffrey M.; Goodson,Harry B.; Maguire,Mark A.; Valencia,Aurelio; Patel,Samir R., Apparatus and method for inserting an intra-aorta catheter through a delivery sheath.
Heilman Marlin S. (1016 Woodhill Dr. Gibsonia PA 15044) Kolenik Steve A. (Rd. 2 ; Box 509 Leechburg PA 15656), Biocompatible ventricular assist and arrhythmia control device.
Heilman Marlin S. (Sarver PA) Kolenik Steve A. (Leechburg PA) Capone Christopher D. (Pittsburgh PA) Parisi Carl M. (Kittanning PA) Prem Edward K. (Allison Park PA) Speicher Vernon L. (Leechburg PA), Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly.
Gencheff Nelson (117 Lakeshore Rd. Grafton WI 53024) Christensen Carl W. (7463 N. Beach Ct. Fox Point WI 53217), Biological material deployment method and apparatus.
Ilbawi Michel N. (1917 Midwest Club Oak Brook IL 60521) Colgate James E. (Evanston IL) Johnson David A. (Evergreen Park IL), Body-implantable device for controlling the size of a fluid passageway.
Heilman Marlin S. (Sarver PA) Kolenik Steve A. (Leechburg PA) Capone Christopher D. (Pittsburgh PA) Parisi Carl M. (Kittanning PA) Prem Edward K. (Allison Park PA) Speicher Vernon L. (Leechburg PA), Cardiac compression band-stay-pad assembly and method of replacing the same.
Wolinsky Harvey (New York NY) King Spencer L. (Atlanta GA) Barbere Michael D. (Dunstable MA), Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen.
Pizon Vronique (7 ; rue Nicolas Houl F-75005 Paris FRX) Farcot Jean-Christian (39 ; rue Spontini F-75016 Paris FRX), Coronary sinus retroperfusion apparatus for the treatment of myocardial ischemia.
Krog Michael (Engelbrektsgatan 4 S-803 24 Gvle SEX) Hllgren Roger (Dragontorpsvgen 9 S-740 22 Blinge SEX) Knutson Lars (Cellovgen 124 E Upsala SEX) Raab Yngve (Cellovgen 124 E S-756 54 Uppsala SEX), Device for segmental perfusion and aspiration of colon and rectum.
Crocker Michael D. (Mission Viejo CA) Henson Michael R. (Pleasonton CA) Chum Muny (Santa Ana CA), Drug delivery and dilatation catheter having a reinforced perfusion lumen.
Ryan Timothy J. (5660 Alpine Rd. Los Altos Hills CA) Fogarty Thomas J. (5660 Alpine Rd. Portola Valley CA 94028) Mollenauer Kenneth H. (Santa Clara CA), Internal graft prosthesis and delivery system.
Milder Fredric L. (Brookline MA) Kung Robert T. V. (Andover MA) Lederman David M. (Marblehead MA) Singh Param I. (Lexington MA), Intra-arterial cardiac support system.
Walker, Blair D.; Higgins, Sheryl W., Low-profile single-lumen dual-balloon catheter with integrated guide wire for embolectomy dilatation/occlusion and delivery of treatment fluid.
Tsitlik Joshua E. ; Levin Howard R. ; Ziselson Naum ; Michelman Paul C., Method and apparatus for assisting a heart to pump blood by applying substantially uniform pressure to the ventricles.
Klein Enrique J. (Los Altos CA) Bajor Jordan (Palo Alto CA) Alba Paul (San Jose CA) Kaplan Aaron V. (Los Altos CA), Method and apparatus for providing external perfusion lumens on balloon catheters.
Krause Horst E. (P.O. Box 617 Freeport TX 77541) Stanley Edwin L. (2566 S. Patterson Blvd. Dayton OH 45409), Method and apparatus for pumping blood within a vessel.
Levin Howard R. ; Gelfand Mark, Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator.
Ya Wang D. (Qian Fo Shan Lu 3 Hao Ji Nan Shi ; Shan Dong Sheng CNX), Method of percutaneously removing a thrombus from a blood vessel by using catheters and system for removing a thrombus f.
Sterman, Wesley D.; Stevens, John H.; Gifford, III, Hanson S.; Siegel, Lawrence C.; Putnam, Joe B., Methods and apparatus for perfusion of isolated tissue structure.
Calderon Reynaldo (1202 Harvard Houston TX 77008), Methods and systems for retrograde perfusion in the body for curing it of the disease or immume deficiency.
Blake Lawrence W. (Costa Mesa CA) Lieber Clement E. (Yorba Linda CA) Swan Harold J. C. (Beverly Hills CA) Ganz William (Los Angeles CA), Multipurpose flow-directed catheter.
Safar Peter (Pittsburgh PA) Stezoski S. William (Pittsburgh PA) Klain Miroslav (Pittsburgh PA), Portable and modular cardiopulmonary bypass apparatus and associated aortic balloon catheter and associated method.
Callol, Joseph R.; Brandt, Brian D.; Matin, Nazanine; Valencia, Hans F.; Wilson, W. Stan; Bigus, Steve; Chi, David; Cho, Brenda, Stent and catheter assembly and method for treating bifurcations.
Nabel Elizabeth G. (Ann Arbor MI) Nabel Gary J. (Ann Arbor MI), Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor.
Stratton Henry T. ; Antonucci Tammy K. ; Schollmayer Erwin,DEX, Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media age.
Azagury, Dan E.; Garrett, Mary K.; Jenkinson, Ronan L.; Lao, Henry; Hulme, Gary B.; Rose, Jacqueline; Landey, Casey, Devices and methods for airway measurement.
Elkins, Jeffrey M.; Valencia, Aurelio; Patel, Samir R.; Aboytes, Ricardo; Goodson, Harry B.; Ball, Craig A., Method and apparatus for intra-aortic substance delivery to a branch vessel.
Elkins, Jeffrey M.; Valencia, Aurelio; Patel, Samir R.; Aboytes, Ricardo; Goodson, Harry B.; Ball, Craig A., Method and apparatus for intra-aortic substance delivery to a branch vessel.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.